Invasive Lancefield group A streptococcal infections in the Netherlands;Invasieve infecties met streptokokken uit lancefield-groep A in Nederland

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 30, 2007, Pages 1669-1673

  Vlaminckx, B J M ^a   Mascini, E M ^b   Schellekens, J F P ^c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c Laboratorium Voor Infectieziekten   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CLINDAMYCIN; IMMUNOGLOBULIN G; M PROTEIN; PENICILLIN G;

ANTIBIOTIC SENSITIVITY; ARTICLE; CELL MEMBRANE; DISEASE SURVEILLANCE; DRUG EFFECT; GENOME; HUMAN; IN VITRO STUDY; MORBIDITY; MORTALITY; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

HUMANS; IMMUNOGLOBULIN G; INCIDENCE; NETHERLANDS; POPULATION SURVEILLANCE; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TIME FACTORS; VIRULENCE;

EID: 34547661484     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Billroth T. In: Reimer G, editor. Untersuchungen über die Vegetationsformen von Coccobacteria septica und den Antheil, welchen sie und der Enstehung und Verbreitung der accidentellen Wundkrankheiten haben u.s.w. Berlijn: C.Reimer; 1874.
2. Lancefield RC. The antigenic complex of Streptococcus haemolyticus. I. Demonstration of a type-specific substance in extracts of Streptococcus haemolyticus. J Exp Med. 1928;47:91-103.
3. Vlaminckx BJM, Pelt W van, Schouls LM, Silfhout A van, Mascini EM, Elzenaar CP, et al. Long-term surveillance of invasive group A streptococcal disease in the Netherlands, 1994-2003. Clin Microbiol Infect. 2005;11:226-31.
4. Muller MP, Low DE, Green KA, Simor AE, Loeb M, Gregson D, et al. Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med. 2003;163:467-72.
5. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321:1-7.
6. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269:390-1.
7. Vlaminckx BJM, Pelt W van, Schouls LM, Silfhout A van, Elzenaar CP, Mascini EM, et al. Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996. Eur J Clin Microbiol Infect Dis. 2004;23:434-44.
8. Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, McGeer A, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis. 2003;9:970-7.
9. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685-94.
10. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34:953-8.
11. Musser JM, Kapur V, Kanjilal S, Shah U, Musher DM, Barg NL, et al. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis. 1993;167:337-46.
12. Choi YJ, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990;172:981-4.
13. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, Mammarella ND, et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA. 2002;99:10078-83.
14. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2006; 2:e5.
15. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23-8.
16. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis. 1993; 167:1401-5.
17. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis. 2001:33 Suppl 2: S84-93.
18. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003; 35:683-9.
19. Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333-40.
20. Cockerill 3rd FR, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA. 1997;277:38-43.
21. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996;335: 547-54.
22. Robinson KA, Rothrock G, Phan Q, Sayler B, Stefonek K, van Beneden C, et al. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis. 2003;9:443-7.